Balchem Corporation 2004 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2004. Balchem Corporation develops, manufactures, and markets specialty performance ingredients for the food, feed, and medical sterilization industries. The Company operates through three segments: Specialty Products (ethylene oxide and other gases), Encapsulated/Nutritional Products (microencapsulation for food and animal health), and BCP Ingredients (choline chloride for animal feed).
Key Financial Metrics
| Metric | 2004 | 2003 |
|---|---|---|
| Net Sales | $67,406,000 | $61,875,000 |
| Gross Margin | $23,806,000 (35.3%) | $21,152,000 (34.2%) |
| Net Earnings | $8,026,000 | $5,638,000 |
| Diluted EPS | $1.03 | $0.75 |
| Operating Cash Flow | $12,145,000 | $11,153,000 |
| Long-Term Debt | $0 | $7,839,000 |
| Cash & Equivalents | $12,734,000 | $9,239,000 |
| Working Capital | $23,505,000 | $17,555,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8.9% to $67.4 million, driven by volume growth in Specialty Products (10% increase) and BCP Ingredients (18.9% increase). Encapsulated/Nutritional Products saw a modest 3% increase despite competitive pricing pressures.
- Profitability: Net earnings rose 42.4% to $8.0 million. Earnings from operations increased 42.0% to $12.8 million, aided by a 9.3% reduction in operating expenses due to organizational changes in the Encapsulated segment.
- Debt Elimination: The Company prepaid the remaining $7.8 million balance of its term loan in Q4 2004, resulting in zero long-term debt at year-end.
- Stock Split: A 3-for-2 stock split was approved in December 2004 and effected in January 2005; all per-share data in this report has been retroactively adjusted.
Outlook, Risks, and Management Commentary
- Guidance: Capital expenditures are projected to be approximately $1.7 million for 2005. The Company expects operations to generate sufficient cash flow for working capital and investments.
- Regulatory Risk: The Company is in the process of re-registering its ethylene oxide product with the EPA under FIFRA requirements. While management believes re-registration will be successful, the EPA has not provided a completion date due to a backlog. This product has no known equally effective substitute.
- Customer Concentration: One customer (Sterigenics) accounted for 11% of net sales in 2004. The loss of this customer could have a material adverse effect.
- Environmental/Legal: The Company faces ongoing monitoring requirements for a former Superfund site in Verona, MO (indemnified by prior owners) and a buried drum site in Slate Hill, NY. There is also pending litigation regarding alleged exposure to ethylene oxide, though management believes the outcome will not be material.
- Accounting Changes: The Company is evaluating the impact of SFAS 123(R) regarding share-based payment, effective 2005, which may require recognizing compensation costs previously excluded.
Investor Verification Checklist
- Verify the status and timeline of the EPA re-registration for ethylene oxide, a critical product with no known substitute.
- Monitor the financial health of Sterigenics, the Company's largest single customer (11% of sales).
- Assess the impact of rising raw material and energy costs on future gross margins, which were already pressured in 2004.
- Review the potential financial impact of adopting SFAS 123(R) on future earnings per share.
- Confirm the renewal of the $3 million revolving credit facility expiring May 30, 2005.